Luke Halpern, Assistant Editor

Subcutaneous administration of atezolizumab and hyaluronidase-tqjs had similar efficacy to intravenous administration.

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

Promising abstracts surrounding DLL3 targeting for patients with lung and neuroendocrine cancer were presented at WCLC 2024.

Highlights from multiple trials investigating novel treatments for mNSCLC were presented at 2024 World Conference on Lung Cancer.

Tocilizumab reduced relapses in 4 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

When IVIG was administered within 48 hours of hospital admission, hospital and ICU length of stay were dramatically shortened.

Presentations highlighted the potential of tarlatamab in treating solid tumor cancers.

Datopotamab deruxtecan was effective in patients with TROP2-QCS biomarker-positive tumors for non–small cell lung cancer

Lazertinib with amivantamab was found to be similar in efficacy to osimertinib in the MARIPOSA study.

Full traditional approval follows accelerated approval of the medication last year.

New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.

Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.

Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.

These companion diagnostics are poised to provide simpler and detailed insights into a patient’s genomic alternations, which could improve outcomes for patients with prostate cancer.

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

Patients with DLBCL on Medicaid had worse survival outcomes than those on commercial insurance, but there were no statistically significant differences in survival between races.

Bezisterim, an anti-inflammatory insulin sensitizer, will be authorized to proceed to a phase 2 clinical trial.

For those with unexplained pregnancy loss, these results could prove promising improvements to birth outcomes.

The request comes as increased scrutiny is levied toward pharmacy benefit managers for alleged unfair business practices.

Pharmacists play an essential role in ensuring the medication is dispensed to patients with high atherosclerotic cardiovascular disease risk.

The use of surrogate markers was observed for breakthrough-designated indications that were approved through both traditional pathways and accelerated pathways.

Jake Galdo and Annie Eisenbeis discuss their vaccine gap closure program and the ability to utilize the model beyond vaccines.

In survivors of lymphoma with fragmented transition of care, preparedness and activation for the next phase of their survivorship was lacking.

In an initiative to close vaccine gaps in local Missouri communities, pharmacists and community health workers proved essential.

Aligning with previous data, the drug combination was modestly effective in patients with large B-cell lymphoma pre- and post-CAR-T-cell therapy.

In an interview with Pharmacy Times, Jasmine Perry describes her idea of an effective health care delivery model and why research can have a huge impact at the policy level.

Bendamustine resulted in a greater risk of treatment complications in patients with lymphoma.

The acceptance will lead to vaccines that provide better protection against the KP.2 strain of SARS-CoV-2.

Drawing on years of experience, Rina Shah explains how sustainable care models are essential for a thriving pharmaceutical industry.

The FDA assigned the combination a Prescription Drug User Fee Act goal date of April 21, 2025.